Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated ARC-HD Trial Shows Successful Maintenance of Chorea Control After Switch to SD-809 NDA Submission Planned by Mid-2015 Conference Call Scheduled for 4:30 PM ET / 1:30 PM PT Today
LA JOLLA, Calif., Dec.
Sign-up for NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that
ASPIRA, a Phase 2 study of duvelisib, an oral inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, with background
methotrexate in patients with moderate-to-severe rheumatoid arthritis
(RA) did not meet its primary endpoint.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.